Albert Labs International Corp. (CNSX: ABRT)
Health Care · Biotechnology · CA
CA$—
— today · — 1Y
Albert Labs International Corp. (CNSX: ABRT) operates in the Biotechnology industry within the Health Care sector. The company is valued at $271.79K.
trading between 0.01 and 0.04.
Tweenvest scores Albert Labs International Corp. across four factors: quality 4/100. Its strongest factor is quality.
ABRT price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $271.79K
- Revenue (TTM)
- —
- P/E
- —
- EPS
- -0.04
- Dividend yield
- —
- Beta (5Y)
- 2.13
- 52-week high
- CA$0.04
- 52-week low
- CA$0.01
- Avg volume (3M)
- —
- Shares outstanding
- 74.41M
- Employees
- —
- Next earnings
- —
About Albert Labs International Corp.
Albert Labs International Corp. is a pharmaceutical research and development company dedicated to addressing urgent and underserved patient needs, particularly in critical mental health. The firm specializes in creating psilocybin-assisted therapies aimed at improving conditions such as anxiety, depression, and the psychological distress linked to cancer. This enterprise operates out of Burnaby, Canada.
- Listed since
- Feb 1, 2023
- Exchange
- Canadian National Stock Exchange
- Currency
- CAD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AbbVie Inc.NYSE: ABBV | $468.22B | $264.96 | +1.20% |
| Amgen Inc.NasdaqGS: AMGN | $237.52B | $439.33 | +1.29% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $181.18B | $146.12 | +1.86% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $138.91B | $548.05 | +1.44% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $83.28B | $834.04 | +0.90% |
| argenx SEENXTBR: ARGX | $65.85B | €883.80 | -2.02% |
| Moderna, Inc.NasdaqGS: MRNA | $57.92B | $142.62 | -1.69% |
| CSL LimitedASX: CSL | $57.77B | AU$168.30 | -1.69% |
Figures last refreshed Aug 18, 2026.